Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia

Trial Profile

Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Inotuzumab ozogamicin (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2017 Planned End Date changed from 1 Apr 2024 to 1 Nov 2023.
    • 01 Dec 2017 Planned primary completion date changed from 1 Apr 2024 to 1 Nov 2023.
    • 01 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top